Dosing of Etelcalcetide and Cinacalcet for Secondary Hyperparathyroidism
| Autor: | Jean-Marc Guettier, Mary T. Thanh Hai, Curtis J. Rosebraugh |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Cinacalcet Urology Parathyroid hormone 01 natural sciences law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Renal Dialysis law medicine Clinical endpoint Humans 030212 general & internal medicine Dosing Etelcalcetide Hyperparathyroidism business.industry General Medicine medicine.disease 0104 chemical sciences Surgery 010404 medicinal & biomolecular chemistry Parathyroid Hormone Calcium Hyperparathyroidism Secondary Secondary hyperparathyroidism business medicine.drug |
| Zdroj: | JAMA. 317:2132 |
| ISSN: | 0098-7484 |
| DOI: | 10.1001/jama.2017.4743 |
| Popis: | To the Editor In the study by Dr Block and colleagues,1 the effect of etelcalcetide on reducing serum parathyroid hormone (PTH) levels in patients with secondary hyperparathyroidism receiving hemodialysis was compared with cinacalcet. This 26-week randomized, double-blind, double-dummy controlled trial was designed to demonstrate noninferiority between 2 calcimimetics for the primary end point of the proportion of patients achieving more than a 30% reduction in PTH levels from baseline. Demonstration of superiority on PTH reduction was a secondary end point. The authors concluded noninferiority and superiority for etelcalcetide compared with cinacalcet. However, comparative claims require a fair comparison between treatments, and the dosing algorithm in this trial appeared to favor etelcalcetide. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|